Cell therapy of brain stroke

Rabinovich, S. S.; Селедцов, В. И.; Banul, N. V.; Повещенко, О. В.; Senyukov, Vladimir; Астраков, С. В.; Самарин, Д. М.; Taraban, Vadim Y.

doi:10.1007/s10517-005-0229-y

Cited by 77 publications

(58 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Promising results from preclinical studies and clinical trials have already been described in several diseases, such as diabetes mellitus [102,103], chronic myeloid leukemia [104,105], cirrhosis [106,107], pulmonary fibrosis [108,109], Crohn’s disease [110,111], heart failure [66,112], and disorders of the nervous system [113,114,115,116,117], and the immunomodulatory effects of stem cells have found their utility in several conditions characterized by predominant inflammation [118,119]. …”

Section: Stem Cells In Clinical Practice and Regenerative Medicinementioning

confidence: 99%

Introduction to Stem Cells and Regenerative Medicine

Kolios

Moodley²

2012

Respiration

369

259

View full text Add to dashboard Cite

Stem cells are a population of undifferentiated cells characterized by the ability to extensively proliferate (self-renewal), usually arise from a single cell (clonal), and differentiate into different types of cells and tissue (potent). There are several sources of stem cells with varying potencies. Pluripotent cells are embryonic stem cells derived from the inner cell mass of the embryo and induced pluripotent cells are formed following reprogramming of somatic cells. Pluripotent cells can differentiate into tissue from all 3 germ layers (endoderm, mesoderm, and ectoderm). Multipotent stem cells may differentiate into tissue derived from a single germ layer such as mesenchymal stem cells which form adipose tissue, bone, and cartilage. Tissue-resident stem cells are oligopotent since they can form terminally differentiated cells of a specific tissue. Stem cells can be used in cellular therapy to replace damaged cells or to regenerate organs. In addition, stem cells have expanded our understanding of development as well as the pathogenesis of disease. Disease-specific cell lines can also be propagated and used in drug development. Despite the significant advances in stem cell biology, issues such as ethical controversies with embryonic stem cells, tumor formation, and rejection limit their utility. However, many of these limitations are being bypassed and this could lead to major advances in the management of disease. This review is an introduction to the world of stem cells and discusses their definition, origin, and classification, as well as applications of these cells in regenerative medicine.

show abstract

Section: Stem Cells In Clinical Practice and Regenerative Medicinementioning

confidence: 99%

Introduction to Stem Cells and Regenerative Medicine

Kolios

Moodley²

2012

Respiration

369

259

View full text Add to dashboard Cite

show abstract

“…The only trial reporting the use of intrathecal route for cell delivery is that of Reabinovich et al (2005) who used a poorly identified cell population consisting of a mixture of immature nervous and hemopoeitic cells (37).…”

Section: Discussionmentioning

confidence: 99%

Intrathecal Autologous Bone Marrow Derived Mesenchymal Stem Cells for Ischemic Stroke: Short Term Safety and Efficacy Study

W¹

2015

BIO

View full text Add to dashboard Cite

Abstract:Background: Preclinical and animal studies provide considerable hope for stem cell therapy in cerebrovascular stroke. This study was designed as a pilot study to explore this provisional data. Autologous bone marrow derived mesenchymal stem cells were chosen due to their proven angiogenic, paracrine and neuroregenerative functions. Subjects and Methods: The present study included 32 patients with ischemic stroke fulfilling the following criteria: Inclusion Criteria: 1. Patients with established stroke in the distribution of the middle cerebral artery territory. 2. Six months at least after the onset of acute ischemic stroke. 3. CT brain at the onset denoting acute ischemic stroke. Exclusion Criteria: 1. Hemorrhagic stroke. 2. Conditions which mimick stroke,e.g., multiple sclerosis, vasculitis, arteriovenous malformations, trauma, tumours. Patients were randomly divided into control group (11 patients) and study group (21 patients) which was further divided according to the time between the onset of the stroke and the beginning of the study into: Group I : onset of the stroke and the beginning of the study :6-12 months( 12 patients: 6 males and 6 females). Group II: onset of stroke and the beginning of the study :13-36 months (9 patients: 5 males and 4 females). Control Group: 11 stroke patients : 6 males and 5 females. Time from onset of stroke to beginning of the study ranged from 6-30 months. Both study and control group were subjected to thorough clinical and laboratory assessment , CT brain, National institutes of Health Stroke Scale (NIHSS) and th Barthel active daily life (ADL) scale at the start of therapy, and at 1,3,6 and 12 months after the start of therapy. Stem Cell Injection: 10 million autologous bone marrow-derived MSCs were injected via lumbar puncture in the study group. Results and Conclusions: Changes in Follow-up Parameters: 1. Changes in NIHSS score: Control group showed non-significant decrease in NIHSS score starting from the 3 rd month. On the other hand, study group showed highly significant decrease in NIHSS score starting from 6 th month, more in group I. 2. Changes in ADL score: ADL score showed non-significant increase starting from 3 rd month in the control group, while it showed a highly significant increase in the study group starting from 6 th month, more pronounced in group I. Intrathecal administration of MSCs is safe and enhances regeneration in ischemic stroke patients.

show abstract

“…Rabinovich et al [80] reported on a case-series, nonrandomized, open-label study that included three patients with hemorrhagic strokes in the middle cerebral artery (MCA) territory and seven patients with ischemic strokes in the MCA territory, with or without additional involvement of the anterior cerebral artery (ACA) territory. Subarachnoidal injections of 2 · 10 8 human fetal cells were made between 4 and 24 months after the disease onset.…”

Section: Human Fetal Cellsmentioning

confidence: 99%

The Rise of Cell Therapy Trials for Stroke: Review of Published and Registered Studies

Rosado-de-Castro

Pimentel‐Coelho

Fonseca

et al. 2013

Stem Cells and Development

View full text Add to dashboard Cite

Stroke is the second leading cause of death and the third leading cause of disability worldwide. Approximately 16 million first-ever strokes occur each year, leading to nearly 6 million deaths. Nevertheless, currently, very few therapeutic options are available. Cell therapies have been applied successfully in different hematological diseases, and are currently being investigated for treating ischemic heart disease, with promising results. Recent preclinical studies have indicated that cell therapies may provide structural and functional benefits after stroke. However, the effects of these treatments are not yet fully understood and are the subject of continuing investigation. Meanwhile, different clinical trials for stroke, the majority of them small, nonrandomized, and uncontrolled, have been reported, and their results indicate that cell therapy seems safe and feasible in these conditions. In the last 2 years, the number of published and registered trials has dramatically increased. Here, we review the main findings available in the field, with emphasis on the clinical results. Moreover, we address some of the questions that have been raised to date, to improve future studies.

show abstract

Cell therapy of brain stroke

Cited by 77 publications

References 4 publications

Introduction to Stem Cells and Regenerative Medicine

Introduction to Stem Cells and Regenerative Medicine

Intrathecal Autologous Bone Marrow Derived Mesenchymal Stem Cells for Ischemic Stroke: Short Term Safety and Efficacy Study

The Rise of Cell Therapy Trials for Stroke: Review of Published and Registered Studies

Contact Info

Product

Resources

About